Skip to main content

Advertisement

Table 5 Comparison of the effects of dapagliflozin on metabolic parameters with or without renal dysfunction

From: A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin

Variables Dapagliflozin (n = 14) p value
eGFR ≥ 70 [mL min−1 (1.73 m2)−1] (n = 6) eGFR < 70 [mL min−1 (1.73 m2)−1] (n = 8)
ΔMAGE (mg dL−1) −3.4 ± 24.1 11.4 ± 31.9 0.34
ΔHbA1c (%) 0.3 ± 0.7 0.6 ± 0.4 0.35
ΔBMI (kg m−2) −1.2 ± 0.4 −0.7 ± 1.1 0.31
  1. Values are mean ± SD. p value of eGFR ≥ 70 vs eGFR < 70
  2. eGFR estimated glomerular filtration rate, MAGE mean amplitude of glycemic excursions, BMI body mass index